Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the American Society of Clinical Psychopharmacology (ASCP) Conference in Scottsdale, Arizona from May 27-30, 2025. The Company's poster presentations will explore the age of onset of social anxiety dis.
- 05/23/2025
|
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented new data on social anxiety disorder (SAD) at the 2025 Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada. The Company's poster presentations examined the age of onset of SAD in participants in.
- 04/17/2025
|
Vistagen to Present at the 2025 Anxiety and Depression Association Conference
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada from April 3 to 5, 2025. The Company's poster presentations will explore the age of onset of social anxiety diso.
- 03/19/2025
|
Vistagen to Participate in Stifel 2025 Virtual CNS Forum
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that management will participate in Stifel's 2025 Virtual CNS Forum. Vistagen's President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat presentation on Tuesday, March 18, 2025, at 12 p.m.
- 03/04/2025
|
Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication
- Vistagen Therapeutics, Inc.'s results from the PALISADE-3 and PALISADE-4 studies, using fasedienol for the treatment of patients with Social Anxiety Disorder, expected in 2025. Fifth proof-of-concept of pherine drug use was achieved targeting patients with cancer cachexia; Further IND enabling efforts underway to begin phase 2 studies for this program in the United States. The global cancer cachexia market size is projected to reach $3.76 billion by 2032.
- 02/14/2025
|
Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript
- Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q3 2025 Earnings Call Transcript February 13, 2025 5:00 PM ET Company Participants Mark McPartland - Senior Vice President of Investor Relations Shawn Singh - Chief Executive Officer and Director Cindy Anderson - Chief Financial Officer Josh Prince - Chief Operating Officer Conference Call Participants John Boyle - William Blair Operator Good day. Thank you for standing by.
- 02/13/2025
|
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates
- VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.22 per share a year ago.
- 02/13/2025
|
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2025 third quarter ended December 31, 2024, and provided a corporate update. “We had a very productive quarter, with both PALISADE-3 and PALISADE-4 advancing towards expected top-line.
- 02/13/2025
|
Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 13, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 third quarter ended December 31, 2024, and provide a.
- 02/06/2025
|
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that the U.S. Patent and Trademark Office (USPTO) granted a patent to the Company for its oral non-opioid product candidate, AV-101, for the treatment of neuropathic pain. The patent will not expire until at least 2034 and is part of Vistage.
- 02/05/2025
|
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in a repeat dose study of fasedienol, its investigational neuroactive pherine nasal spray in Phase 3 development for the acute treatment of social anxiety disorder (SAD). The repeat dose study is a small exploratory U.S. Phase 2 multi-center, randomized, double-blind, place.
- 01/10/2025
|
Vistagen to Present at the Stifel 2024 Healthcare Conference
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Healthcare Conference taking place November 18 and 19, 2024 in New York City. Stifel 2024 Healthcare Conference Shawn Singh, Chief Executive Officer, will participate in a fireside chat on Monday, November 18 at 3:35.
- 11/14/2024
|
Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript
- Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q2 2025 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Mark McPartland - SVP, IR Shawn Singh - CEO Cindy Anderson - CFO Josh Prince - COO Conference Call Participants Julian Pino - Stifel Andrew Tsai - Jefferies Myles Minter - William Blair Madison El-Saadi - B. Riley Securities Operator Good afternoon, ladies and gentlemen, and welcome to the Vistagen Therapeutics Fiscal Year 2025 Second Quarter Corporate Update Conference Call.
- 11/10/2024
|
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates
- VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.66 per share a year ago.
- 11/07/2024
|
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 second quarter ended September 30, 2024, and provided a corporate update. “We initiated our PALISADE-4 Phase 3 trial during our second quarter, achieving yet another significant milestone in our fasedienol U.S. registration-directed Phase 3 Program for the acute t.
- 11/07/2024
|
Vistagen to Present at the 2024 Neuroscience Education Institute Congress
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that it will present posters highlighting new prevalence data for social anxiety disorder (SAD), an indication for which fasedienol, its lead intranasal pherine product candidate, is in U.S. registration-directed Phase 3 development for the acute treatment of the disorder, and two additional non-systemic.
- 11/05/2024
|
Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Thursday, November 7, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 second quarter ended September 30, 2024, and provide a corporate update. Event: Vistagen Fiscal Year 2025 Second Quarter Corporate Update.
- 11/01/2024
|
Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder
- Vistagen's fasedienol nasal spray is in two phase 3 trials for social anxiety disorder, with results expected in 2025. Positive results from PALISADE-2 were seen previously, and VTGN may need only one of the two studies, PALISADE-3 and PALISADE-4, to succeed in supporting a filing for marketing approval. VTGN had $108.4M as of June 30, 2024, but increased R&D expenses may accelerate cash burn, and the Company could look to use its at-the-market facility or conduct an offering.
- 10/15/2024
|
VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know
- VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 10/11/2024
|
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day
- SOUTH SAN FRANCISCO, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development of groundbreaking therapies for psychiatric disorders based on nose-to-brain neurocircuitry, and The Goldie Hawn Foundation's MindUP, a neuroscience-based preventative mental health program for youth, along with children from New York City schools utilizing MindUP, will join together in New York City on Oc.
- 10/09/2024
|
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN) a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in its PALISADE-4 Phase 3 trial of fasedienol, an investigational neuroactive pherine nasal spray in U.S. registration-directed Phase 3 development for.
- 09/23/2024
|
All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy
- VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 09/06/2024
|
Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript
- Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2025 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Mark McPartland - SVP, IR Shawn Singh - CEO Cindy Anderson - CFO Josh Prince - COO Conference Call Participants Andrew Tsai - Jefferies Tim Lugo - William Blair Madison Elsaadi - B. Riley Securities Operator Ladies and gentlemen, greetings and welcome to Vistagen Therapeutics Fiscal Year 2025 First Quarter Corporate Update Conference Call.
- 08/13/2024
|
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates
- VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.94 per share a year ago.
- 08/13/2024
|
3 Stocks Under $15 That Could Make You a Millionaire
- Lately, the stock market has been soaring thanks mostly to growth stocks trading at sky-high valuations. While rate cuts could potentially boost markets, caution is still warranted for most investors.
- 07/26/2024
|
Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript
- Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q4 2024 Earnings Conference Call June 11, 2024 5:00 PM ET Company Participants Mark McPartland - Senior Vice President, Investor Relations Shawn Singh - Chief Executive Officer Cindy Anderson - Chief Financial Officer Josh Prince - Chief Operating Officer Conference Call Participants Tim Lugo - William Blair Operator Greetings, and welcome to the Vistagen Therapeutics Fiscal Year-End 2024 Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
- 06/11/2024
|
Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year ended March 31, 2024, and provided a corporate update. “Vistagen's fiscal 2024 proved to be a year full of remarkable accomplishments. Most notably, with.
- 06/11/2024
|
Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced it will host a conference call and webcast on Tuesday, June 11, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2024 ended March 31, 2024 and provide a corporate update. Event: Vistagen Fis.
- 06/07/2024
|
Vistagen to Present at the Jefferies Global Healthcare Conference
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the Jefferies Global Healthcare Conference taking place June 5 and 6, 2024 in New York City. Jefferies Global Healthcare Conference Shawn Singh, Chief Executive Of.
- 05/29/2024
|
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters highlighting fasedienol, its investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and itruvone, its investigational pherine candidate in Phase 2.
- 05/23/2024
|
3 Must-Have Penny Stocks to Boost Your 2024 Portfolio
- Penny stocks can be super volatile, but the potential of a modest investment ballooning into a multi-bagger is tough to pass up. These stocks represent the riskier end of the public equity range.
- 05/14/2024
|
Meme Stock Rebound: 3 Reddit Favorites Primed for a Resurgence
- The hype train is always talking about meme stocks set for a rebound on Reddit (NASDAQ: RDDT ). I try my best to avoid these large echo chambers of misinformation.
- 05/13/2024
|
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the 2024 RBC Capital Markets Global Healthcare Conference taking place May 14 and 15, 2024 in New York City. 2024 RBC Capital Markets Global Healthcare Conference Shawn Singh, Chief E.
- 05/07/2024
|
PRISM MarketView – Weekly Market Report – April 26, 2024
- PRISM Market Pulse: Equities Rally Amid Mixed Big Tech Earnings; Economic Shifts and Sector-Specific Highlights New York, N.Y., April 26, 2024 – PRISM MarketView – Equities were higher through the morning into midday trading as the S&P 500 and Nasdaq are set to snap their three- and four-week losing streaks.
- 04/26/2024
|
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced positive results from a Phase 2A pilot study of PH15, an investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue. PH15 demonstrated a statistically significant improvement in reaction time compared to placebo.
- 04/25/2024
|
7 Stocks Under $15 Predicted to Boom in the Next 2 Years
- If you're searching for stocks under $15, look no further. These seven offerings, all priced below $15, present a unique opportunity for individual investors to profit from future development.
- 04/19/2024
|
Millionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027
- Finding possibilities in investing frequently depends on finding companies attached to rapid expansion and value generation. Examine these three prospects, each selling at less than $10 per share and expected to see significant returns by 2027.
- 04/09/2024
|
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters detailing clinical trial data for fasedienol, an investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and PH80, a Phase 2 investigational pherine.
- 04/09/2024
|
Secret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027
- Finding undiscovered opportunities can result in significant profits in an investment landscape frequently controlled by well-known giants. These three obscure stocks have the potential to provide impressive profits.
- 03/31/2024
|
Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish
- Vistagen Therapeutics has proprietary platform technologies for developing innovative drugs for mental health disorders. The company's pipeline includes candidates for social anxiety disorder, major depressive disorder, vasomotor symptoms, and more. Vistagen's financial position is strong, with ample liquidity to support operations and fund clinical development programs.
- 03/20/2024
|
Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments
- VistaGen Therapeutics is developing CNS drugs for anxiety, depression, and other disorders, with Fasedienol in phase 3 clinical trials. Fasedienol has advantages as a non-systemic, low-abuse anxiolytic and is seeking Breakthrough Therapy Designation. VTGN's diverse product pipeline includes treatments for social anxiety disorders, major depressive disorder, menopause symptoms, and more.
- 03/17/2024
|
This overlooked corner of women's health could be a $350 billion market opportunity
- Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.
- 03/15/2024
|
Vistagen to Present at Stifel 2024 Virtual CNS Days
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Virtual CNS Days taking place March 19 to 20, 2024. Stifel 2024 Virtual CNS Days Shawn Singh, Chief Executive Officer, will participate in a fireside chat on Wednesday.
- 03/11/2024
|
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings at the TD Cowen 44th Annual Health Care Conference in Boston, Massachusetts, March 4 to 6, 2024. TD Cowen 44th Annual Health Care Conference Shawn Singh, Chief Executive Officer, will presen.
- 02/28/2024
|
Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?
- The mean of analysts' price targets for VistaGen Therapeutics, Inc. (VTGN) points to a 160% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 02/21/2024
|
3 Revolutionary Biotech Stocks Poised for 10X Surge
- Investing in high-potential biotech stocks should catapult your portfolio to new heights. Picture this: a global biotech market valued at a whopping $1.55 trillion in 2023 is set to catapult to $3.08 trillion by 2030, with a compound annual growth rate of 14%.
- 02/19/2024
|
Vistagen Therapeutics, Inc. (VTGN) Q3 2024 Earnings Call Transcript
- Vistagen Therapeutics, Inc. (VTGN) Q3 2024 Earnings Call Transcript
- 02/13/2024
|
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today reported financial results for its fiscal year 2024 third quarter ended December 31, 2023 and provided a corporate update. "Momentum from clinical and corporate milestones achieved through the end of last quarter have significantly advanced our efforts to develop and co.
- 02/13/2024
|
3 Penny Stocks to Buy for the Next Bull Run: February 2024
- Entering 2024, a shift toward optimism emerges in the market, with eased monetary policies potentially opening doors for penny stocks to rebound. Savvy investors, drawn to overlooked opportunities, may find penny stocks appealing for their explosive long-term gains with even a modest investment.
- 02/07/2024
|
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today announced it will host a conference call and webcast on Tuesday, February 13, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2024 third quarter ended December 31, 2023 and provide a corporate update. Event: Vistagen Fiscal.
- 02/06/2024
|
3 Penny Stocks to Turn $999 Into $1 Million: January 2024
- Despite the recent economic deceleration, positive factors like a tight labor market and strong consumer spending support a resilient U.S. economy. Goldman Sachs predicts increased state and local government spending, and overall expectations suggest that, while there may be a short slowdown, the U.S. economy is anticipated to remain on a positive trajectory in 2024.
- 01/26/2024
|
How Vistagen (VTGN) Stock Stands Out in a Strong Industry
- Vistagen (VTGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 12/29/2023
|
VistaGen: Positive Data Leads To Catalysts In 2024 And Beyond
- Positive results achieved in phase 3 PALISADE-2 study for Fasedienol, a potential new treatment for social anxiety disorder. It is estimated that there are roughly 25 million people in the United States with this disorder. Itruvone is being advanced for the treatment of patients with major depressive disorder; A phase 2b study is expected to start in the 2nd half of 2024.
- 12/22/2023
|
Vistagen Therapeutics, Inc. (VTGN) Q2 2024 Earnings Call Transcript
- Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q2 2024 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Mark McPartland - Senior Vice President, Investor Relations Shawn Singh - Chief Executive Officer Cindy Anderson - Chief Financial Officer Josh Prince - Chief Operating Officer Conference Call Participants Andrew Tsai - Jefferies Tim Lugo - William Blair Operator Good day, everyone and welcome to today's Vistagen Fiscal Year 2024 Second Quarter Corporate Update Conference Call. [Operator Instructions] Please note this call is being recorded.
- 11/10/2023
|
The 7 Best Short-Squeeze Stocks to Buy Now: September 2023
- The best short-squeeze stocks to buy now can be a perilous territory in the investment landscape. However, they also possess the potential for astronomical returns.
- 09/21/2023
|
Vistagen Therapeutics, Inc. (VTGN) Q1 2024 Earnings Call Transcript
- Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2024 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Mark Flather - VP of IR Shawn Singh - CEO Josh Prince - SVP of Business Operations Conference Call Participants Andrew Tsai - Jefferies Joanne Lee - Maxim Group Operator Greetings, and welcome to the Vistagen Therapeutics Fiscal Year 2024 First Quarter Corporate Update Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded, Thursday, August 10, 2023.
- 08/13/2023
|
Outperforming Biotech Pops on Shareholder Buzz
- Vistagen Therapeutics Inc (NASDAQ:VTGN) is continuing its recent volatility, after today's news that healthcare investment name Commodore Capital Master LP has become a top shareholder with a 19.7% stake.
- 08/10/2023
|
Why Is Vistagen Therapeutics (VTGN) Stock Up 650% Today?
- Vistagen Therapeutics (NASDAQ: VTGN ) stock is surging to impressive levels today on news of some positive trial results. The pharmaceutical producer has been struggling all year, dipping into penny stock status and coming dangerously close to the $1 per share mark.
- 08/07/2023
|
2 Biotech Stocks Staging Large Swings
- Sage Therapeutics Inc (NASDAQ:SAGE) is crumbling to record lows today, down 52.2% at $17.25 at last check, earlier hitting a low of $16.69.
- 08/07/2023
|
VistaGen Therapeutics (VTGN Stock) Exploded 3,471% Here's Why
- Are you looking for penny stocks to buy? Are you grappling with the push and pull of skeptics saying penny stocks aren't worth it or penny stocks are a scam?
- 08/07/2023
|
Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Wednesday, June 28, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to report results for its fiscal year 2023 ended March 31, 2023 and provide a corporate update. Event: Vi.
- 06/27/2023
|
Vistagen to Present at Jefferies 2023 Global Healthcare Conference
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that its Chief Executive Officer, Shawn Singh, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference taking place June 7 – 9, 2023 in New York City, NY. Jefferies 2023 Global Healthcare Co.
- 06/06/2023
|
Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that safety and exploratory efficacy data from its Phase 3 open-label study of fasedienol (PH94B) nasal spray for the treatment of adults with social anxiety disorder (SAD) will be presented in a late-breaking poster prese.
- 05/30/2023
|
What to Look For When Finding Penny Stocks to Buy, 3 Tips
- Use these tips for finding penny stocks to buy in 2023 The post What to Look For When Finding Penny Stocks to Buy, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 03/23/2023
|
VistaGen Therapeutics, Inc. (VTGN) Q3 2023 Earnings Call Transcript
- VistaGen Therapeutics, Inc. (NASDAQ:VTGN ) Q3 2023 Earnings Conference Call February 7, 2023 5:00 PM ET Company Participants Mark Flather - Vice President of Investor Relations Shawn Singh - Chief Executive Officer Jerrold Dotson - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies LLC Timothy Lugo - William Blair & Company LLC Operator Greetings. Welcome to VistaGen Therapeutics Third Quarter Fiscal Year 2023 Results Conference Call.
- 02/10/2023
|
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates
- VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 16.67% and 41.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/07/2023
|
Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023
- SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Tuesday, February 7, 2023, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report financial results for its fiscal year 2023 third quarter ended December 31, 2022 and provide a corporate update.
- 02/06/2023
|
The 3 Biggest Impacts on Penny Stocks Prices
- These factors are the main causes of penny stocks price movement The post The 3 Biggest Impacts on Penny Stocks Prices appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 02/01/2023
|
3 Penny Stocks Under $1 To Watch This Week
- Penny Stocks To Watch Under $1 This Week. The post 3 Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/11/2023
|
What Makes VistaGen Therapeutics, Inc. (VTGN) a New Buy Stock
- VistaGen Therapeutics, Inc. (VTGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 11/15/2022
|
VistaGen Therapeutics, Inc. (VTGN) Q2 2023 Earnings Call Transcript
- VistaGen Therapeutics, Inc. (NASDAQ:VTGN ) Q2 2023 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Mark Flather - Vice President of Investor Relations Shawn Singh - Chief Executive Officer Jerry Dotson - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Tim Lugo - William Blair Operator Good day, and welcome to the VistaGen Second Quarter Fiscal Year 2023 Results Conference Call. Today's conference is being recorded.
- 11/10/2022
|
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates
- VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 0% and 388.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/10/2022
|
Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022
- SOUTH SAN FRANCISCO, Calif.
- 11/04/2022
|
Vistagen to Present at Stifel 2022 Healthcare Conference
- SOUTH SAN FRANCISCO, Calif.
- 11/03/2022
|
4 Top Penny Stocks To Watch This Week
- Penny stocks to watch this week. The post 4 Top Penny Stocks To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/26/2022
|
Top Reasons for Investing in Penny Stocks in 2022
- Are penny stocks worth investing in right now or not? The post Top Reasons for Investing in Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/10/2022
|
3 High Volume Penny Stocks To Watch Before Next Week
- Here's what you need to know about buying penny stocks on September 9th, 2022 The post 3 High Volume Penny Stocks To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/09/2022
|
Hot Penny Stocks To Buy For Under $0.99 This Week
- Penny stocks under $1 to watch this week. The post Hot Penny Stocks To Buy For Under $0.99 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/08/2022
|
Penny Stocks To Buy? 3 Under $0.99 For Your Watch List
- Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?
- 08/17/2022
|
VistaGen Therapeutics, Inc.'s (VTGN) CEO Shawn Singh on Q1 2023 Results -Earnings Call Transcript
- VistaGen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2023 Earnings Conference Call August 11, 2022 5:00 PM ET Company Participants Mark Flather – Vice President-Investor Relations Shawn Singh – Chief Executive Officer Jerry Dotson – Chief Financial Officer Conference Call Participants Brian Skorney – Baird Operator Welcome to the VistaGen Therapeutics First Quarter Fiscal Year 2023 Results Conference Call. [Operator Instructions] I'll now turn the call over to your host, Mark Flather, Vice President of Investor Relations.
- 08/12/2022
|
What to Know About Buying Penny Stocks on July 26th
- Here's what you need to know about trading penny stocks on July 26th The post What to Know About Buying Penny Stocks on July 26th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/26/2022
|
What to Know About Trading Penny Stocks in August
- Check these tips out for trading penny stocks in August The post What to Know About Trading Penny Stocks in August appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/23/2022
|
VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q4 2022 Results - Earnings Call Transcript
- VistaGen Therapeutics, Inc. (NASDAQ:VTGN ) Q4 2022 Earnings Conference Call June 23, 2022 5:00 PM ET Company Participants Mark Flather - Vice President of Investor Relations Shawn Singh - Chief Executive Officer Jerrold Dotson - Vice President, Chief Financial Officer and Secretary Mark Smith - Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies LLC Lachlan Hanbury-Brown - William Blair & Company, LLC Luke Herrmann - Robert W. Baird & Co. Michael Okunewitch - Maxim Group LLC Operator Greetings, welcome to the VistaGen Therapeutics' 2022 Fiscal Year-End Results Conference Call.
- 06/23/2022
|
VistaGen Therapeutics, Inc. (VTGN) Reports Q4 Loss, Misses Revenue Estimates
- VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -33.33% and 88.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 06/23/2022
|
VistaGen Therapeutics to Report Fiscal Year 2022 Financial Results on June 23, 2022
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc. (NASDAQ: VTGN) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, today announced it will host a conference call and webcast on Thursday, June 23, 2022, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report its financial results for fiscal year 2022 ending on March
- 06/17/2022
|
VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting
- SOUTH SAN FRANCISCO--(BUSINESS WIRE)--VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today announced that the clinical trial abstract for its exploratory Phase 2A clinical study in adjustment disorder with anxiety (AjDA) for PH94B, its investigational rapid-onset pherine nasal spray with
- 06/02/2022
|
Hot Penny Stocks For Your Buy List This Month? 3 to Watch
- Which penny stocks are you watching in June? The post Hot Penny Stocks For Your Buy List This Month?
- 05/31/2022
|
VistaGen to Participate in Upcoming June Investor Conferences
- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, today announced that Shawn Singh, Chief Executive Officer, will participate in the following upcoming investor conferences in June. Management will be available for one-on-one meetings during these confere
- 05/27/2022
|
7 Cheap Biotech Stocks to Buy Now
- These biotech stocks are speculative, but could potentially blow up in the next couple of years with new treatments in the pipelines. The post 7 Cheap Biotech Stocks to Buy Now appeared first on InvestorPlace.
- 05/19/2022
|
VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q3 2022 Results - Earnings Call Transcript
- VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q3 2022 Results - Earnings Call Transcript
- 02/10/2022
|
VistaGen Therapeutics to Report Fiscal Year 2022 Third Quarter Financial Results on February 10, 2022
- SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (CNS) disorders, will host a conference call and webcast on Thursday, February 10, 2022 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report its financial results for its fiscal year 2022 third quarter ended December 31, 2021 and provide a review of recent accomplishments and anticipated upcoming milestones.
- 02/07/2022
|
VistaGen Therapeutics' (VTGN) CEO Shawn Singh on Q2 2022 Results - Earnings Call Transcript
- VistaGen Therapeutics' (VTGN) CEO Shawn Singh on Q2 2022 Results - Earnings Call Transcript
- 11/10/2021
|
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Tops Revenue Estimates
- VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -40.00% and 9.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/10/2021
|
VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder
- Study Launches Phase 2A Clinical Program Designed to Explore PH94B's Potential in Multiple Additional Anxiety Disorders
- 10/14/2021
|
VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation of PALISADE-2
- PALISADE Phase 3 Program focused on PH94B's potential as a rapid-onset, acute treatment of anxiety in adults with social anxiety disorder PALISADE Phase 3 Program focused on PH94B's potential as a rapid-onset, acute treatment of anxiety in adults with social anxiety disorder
- 09/13/2021
|
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates
- VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 20.00% and -4.58%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/12/2021
|
VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q1 2022 Results - Earnings Call Transcript
- VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q1 2022 Results - Earnings Call Transcript
- 08/12/2021
|
Recap: VistaGen Therapeutics Q1 Earnings
- Shares of VistaGen Therapeutics (NASDAQ:VTGN) fell 1.5% in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 42.86% over the past year to ($0.04), which beat the estimate of ($0.05).
- 08/12/2021
|
VistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update
- PALISADE Phase 3 Program to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) progressing on plan
- 08/12/2021
|
VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference
- SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that management will participate in the Canaccord Genuity 41st Annual Growth Conference including a fireside chat with Shawn Singh, Chief Executive Officer, on Wednesday, August 11 at 1:30 p.m. PT. VistaGen will also be participating in one-on-one meetings throughout the conference.
- 08/02/2021
|
VistaGen Therapeutics to Participate in William Blair Biotech Focus Conference 2021
- SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that management will participate in the ‘Updates in Neuropsych' panel at the virtual William Blair Biotech Focus Conference 2021 on July 15, 2021 at 9:00 a.m. PT. VistaGen will also be participating in one-on-one meetings throughout the conference.
- 07/09/2021
|
VistaGen Therapeutics Announces Appointment of Mary L. Rotunno to its Board of Directors
- Ms. Rotunno brings extensive healthcare industry expertise as a leader and strategist as VistaGen advances late-stage development of its product candidates for anxiety and depression disorders Ms. Rotunno brings extensive healthcare industry expertise as a leader and strategist as VistaGen advances late-stage development of its product candidates for anxiety and depression disorders
- 07/07/2021
|
Are These 8 Penny Stocks to Watch on Your List Right Now?
- Making a penny stocks watchlist for 2021? Check these 8 out The post Are These 8 Penny Stocks to Watch on Your List Right Now?
- 06/30/2021
|
VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q4 2021 Results - Earnings Call Transcript
- VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q4 2021 Results - Earnings Call Transcript
- 06/29/2021
|
VistaGen Therapeutics: Q4 Earnings Insights
- Shares of VistaGen Therapeutics (NASDAQ:VTGN) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 328.57% over the past year to ($0.30), which missed the estimate of ($0.05).
- 06/29/2021
|
VistaGen Therapeutics Reports Fiscal Year 2021 Financial Results and Provides Corporate Update
- PALISADE-1 Phase 3 trial underway to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD)
- 06/29/2021
|
8 Penny Stocks to Watch Right Now As June Comes to an End
- Which penny stocks are investors watching as June comes to an end? The post 8 Penny Stocks to Watch Right Now As June Comes to an End appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/27/2021
|
VistaGen Therapeutics to Report 2021 Fiscal Year End Financial Results, Provide a Business Update and Host Conference Call and Webcast June 29, 2021
- SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that it will host a corporate update conference call on Tuesday, June 29, 2021 at 2:00 pm Pacific Time (5:00 pm Eastern Time) to discuss its financial and operating results for its fiscal year ended March 31, 2021 and provide a business update.
- 06/25/2021
|
Sage Stock Declines on Late-Stage Depression Study Data
- Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.
- 06/16/2021
|
VistaGen Therapeutics Set to Join the Russell 2000® Index
- SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced the Company will be added to the Russell 2000® Index at the conclusion of the 2021 Russell Indexes annual reconstitution, effective after the U.S. market opens on Monday, June 28, 2021, according to a preliminary list of additions posted on June 4, 2021.
- 06/16/2021
|
7 A-Rated Biotech Stocks to Buy Now
- Investors in search of long-term growth are increasingly choosing biotech stocks like BNTX stock and MRNA stock for their portfolios. The post 7 A-Rated Biotech Stocks to Buy Now appeared first on InvestorPlace.
- 06/15/2021
|
5 Buy-Rated Stocks Trading Below $10 With Outstanding Upside Potential
- While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
- 06/12/2021
|
VistaGen Kick Starts Late-Stage Social Anxiety Disorder Study with PH94B
- VistaGen Therapeutics Inc (NASDAQ: VTGN) has initiated its PALISADE Phase 3 study to evaluate PH94B for the acute treatment of Social Anxiety Disorder (SAD). PH94B is an odorless, rapid-onset, investigational pherine nasal spray.
- 05/26/2021
|
VTGN Stock Price: 9.3% Increase Explanation
- The stock price of Vistagen Therapeutics Inc (NASDAQ: VTGN) increased by 9.3% on Friday, May 21. This is why it happened.
- 05/23/2021
|
5 Penny Stocks Analysts Say To Buy With Targets Up To 219% Right Now
- Analysts say these are penny stocks to buy right now & have bullish targets to back it up. The post 5 Penny Stocks Analysts Say To Buy With Targets Up To 219% Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/23/2021
|
Vistagen Therapeutics (VTGN) Stock: Over 14% Increase Pre-Market Explanation
- The stock price of Vistagen Therapeutics Inc (NASDAQ: VTGN) increased by over 14% pre-market. This is why it happened.
- 05/20/2021
|
Hot Penny Stocks to Watch; Is it Time to Buy The Biotech Dip?
- Penny stocks present opportunities to buy the dip often; is that the case with these biotech stocks? The post Hot Penny Stocks to Watch; Is it Time to Buy The Biotech Dip?
- 04/29/2021
|
Penny Stocks Watchlists and How to Make One
- Penny stock watchlists? Why they're not as complicated as they seem The post Penny Stocks Watchlists and How to Make One appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/28/2021
|
Novel Anxiety and Depression Approach by VistaGen Therapeutics
- The COVID-19 pandemic has exacerbated mental health issues and is triggering new conditions for people already suffering from mental illnesses and substance abuse. Social anxiety disorder (SAD) is one of the most prevalent mental health conditions in the U.S., affecting 20 million Americans.
- 04/27/2021
|
VistaGen: Phase 2 Success In Anxiety Disorder, Phase 3 To Begin
- VistaGen has had a tumultuous history, but recent trials have seen success. They may start phase 3 trials for PH94B in May.
- 04/25/2021
|
VistaGen Therapeutics to Participate in Upcoming Investor Conferences in March
- SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced that Shawn Singh, VistaGen's Chief Executive Officer, will participate in the following investor conferences in March:
- 03/16/2021
|
VistaGen's PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study
- PH10 may have stand-alone potential to displace current oral antidepressants in the drug treatment paradigm for depression disorders PH10 may have stand-alone potential to displace current oral antidepressants in the drug treatment paradigm for depression disorders
- 03/11/2021
|
VTGN Stock Price Increases Over 13% Pre-Market: Why It Happened
- The stock price of Vistagen Therapeutics Inc (NASDAQ: VTGN) has increased by over 13% pre-market as of 7:01 AM ET. This is why it happened.
- 02/18/2021
|
VistaGen Therapeutics Reports Fiscal 2021 Third Quarter Financial Results and Provides Update on Expected Clinical Studies in Calendar 2021
- Multiple clinical studies anticipated to launch in Calendar 2021, notably pivotal Phase 3 clinical studies of PH94B as a potential acute treatment of anxiety in adults with social anxiety disorder (SAD)
- 02/11/2021
|
VistaGen: Patience Could Lead To Significant Upside
- VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a generation of novel medicines for anxiety, depression, and other central nervous system disorders, primarily through nasal sprays. VistaGen has three therapeutics in their pipeline across 14 indications. VistaGen's lead therapeutic, PH94B, is an FDA-fast-tracked neuroactive nasal spray aiming to initiate recruitment for a Phase 3 in 2Q2021.
- 01/24/2021
|
VistaGen Announces Publication in CNS Spectrums Detailing Proposed Mechanism of Action of Its Investigational Neuroactive Nasal Sprays for Anxiety and Depression Disorders
- Dr. Louis Monti, VistaGen's Newly-Appointed Vice President, Translational Medicine, and Dr. Michael Liebowitz, VistaGen CNS Clinical and Regulatory Advisory Board Member, Collaborate on Review Dr. Louis Monti, VistaGen's Newly-Appointed Vice President, Translational Medicine, and Dr. Michael Liebowitz, VistaGen CNS Clinical and Regulatory Advisory Board Member, Collaborate on Review
- 12/30/2020
|
VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering
- SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN) (“VistaGen”), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced the closing of its $100 million underwritten public offering consisting of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share (the “Common Stock”), and 2,000,000 shares of its Series D convertible preferred stock (“Series D Preferred Stock”) at a public offering price of $21.16 per share. All of the securities in the offering were sold by VistaGen.
- 12/22/2020
|
Why BioCryst, VistaGen And Teladoc Are Moving Today
- VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher after Maxim raised its price target on the stock from $3 to $5. VistaGen Therapeutics is a biotechnology firm.
- 12/22/2020
|
VistaGen Therapeutics Announces Pricing of Underwritten Public Offering
- SOUTH SAN FRANCISCO, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced the pricing of its underwritten public offering consisting of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share (the “Common Stock”), and 2,000,000 shares of its Series D convertible preferred stock (“Series D Preferred Stock”) at a public offering price of $21.16 per share.
- 12/18/2020
|
VistaGen Therapeutics Announces Proposed Underwritten Public Offering
- SOUTH SAN FRANCISCO, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced that it commenced an underwritten public offering of units consisting of its common stock, par value $0.001 per share (the “Common Stock”), and its Series D convertible preferred stock (the “Series D Preferred Stock”). All securities to be sold in the offering are to be sold by VistaGen. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- 12/17/2020
|
VistaGen Therapeutics Reports Fiscal 2021 Second Quarter Financial Results and Provides Highlights on its CNS Pipeline and Business Progress
- SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today reported its financial results for the fiscal...
- 11/12/2020
|
